Patents for concentrated ultra-rapid insulins

Arecor secures new patents for AT278, targeting a $3 billion US insulin market segment.

What the company is saying

Arecor Therapeutics plc is announcing the grant of new patents for its ultra-concentrated, ultra-rapid acting insulin AT278 in Europe, the United States, and India, extending protection in these markets to at least 2039. The company frames this as a major step in enabling next-generation automated insulin delivery (AID) systems, emphasizing the uniqueness of AT278 as the only 500 U/mL ultra-rapid insulin in development. The narrative highlights the large unmet need in the US, where only ~40% of Type 1 and ~5% of Type 2 diabetes patients use AID systems, and positions Arecor’s insulins as critical to unlocking longer wear, miniaturized, and fully closed loop AID systems. The company claims its products address a $3 billion insulin revenue opportunity within a $5 billion total US market, focusing on patients requiring high daily insulin doses or longer wear times. The tone is confident and opportunity-driven, with Dr Jan Jezek (CSO), Dr Sarah Howell (CEO), and David Ellam (CFO) named as key executives. The announcement stresses robust intellectual property, but does not mention clinical trial progress, regulatory submissions, or commercial partnerships.

What the data suggests

The announcement confirms that Arecor now holds over 30 granted patents for its concentrated ultra-rapid insulins, including new protection for AT278 in Europe, the US, and India, with patent terms extended to at least 2039. AT278 is specified as a 500 U/mL product, and the company’s other candidate, AT290, is 200 U/mL. In the US, approximately four million people with diabetes require intensive insulin therapy and are candidates for AID systems, but current market penetration is low: only ~40% of Type 1 and ~5% of Type 2 patients use AID systems. The company identifies two key underserved groups: about one million US patients needing more than 100 units of insulin per day, and another one million AID users seeking longer wear times and smaller pumps, both currently limited by cartridge size and insulin concentration. The highest unmet need segment is valued at approximately $3 billion in US insulin revenue, with the total US insulin market at $5 billion. While the patent grants are real and the market sizing is specific, there is no evidence of clinical, regulatory, or commercial progress for AT278 or AT290. The claims about enabling full closed loop systems and capturing market share remain forward-looking and unsubstantiated by product adoption or trial data.

Analysis

The announcement is upbeat, highlighting the expansion of Arecor's patent portfolio for AT278 in major markets and emphasizing large addressable market opportunities. The realised, measurable progress is the granting of patents in Europe, the U.S., and India, and the accumulation of over 30 granted patents. However, the bulk of the commercial claims—such as being the first to enable a full closed loop AID system, addressing multi-billion-dollar market segments, and unlocking new revenue opportunities—are forward-looking and not yet realised. There is no disclosure of clinical, regulatory, or commercial milestones achieved, nor any financial performance data (revenue, profit, cash flow) to support operational progress. The narrative inflates the signal by repeatedly referencing the size of the opportunity and unmet needs, but provides no evidence of product adoption, clinical validation, or near-term commercialisation. The gap between narrative and evidence is moderate: the IP progress is real, but the commercial impact is speculative and long-dated.

Risk flags

• ●Commercialization risk is high: while the addressable US insulin market is estimated at $5 billion and the highest unmet need segment at $3 billion, there is no evidence of product adoption, clinical trial results, or regulatory progress for AT278 or AT290. Without these, market entry and revenue realization remain speculative.
• ●Execution risk is significant: the company’s claims about enabling next-generation AID systems and capturing large market segments depend on successful clinical development, regulatory approval, and partnerships with insulin pump manufacturers, none of which are disclosed as achieved.
• ●Competitive risk exists: large, multi-billion-dollar insulin pump companies are also pursuing longer wear and miniaturized AID systems, and there is no evidence that Arecor’s insulins will be first to market or preferred by device manufacturers.
• ●Disclosure risk is present: the announcement provides detailed IP and market sizing data but omits any financial performance, clinical progress, or partnership agreements, making it difficult for investors to assess operational momentum or near-term catalysts.

Bottom line

Arecor’s new patents for AT278 in Europe, the US, and India extend its intellectual property protection to at least 2039 and reinforce its position in the concentrated, ultra-rapid insulin space. The company quantifies a $3 billion US revenue opportunity among high-need diabetes patients, within a $5 billion total US insulin market, but provides no evidence of clinical, regulatory, or commercial progress toward capturing this market. The narrative is credible on the IP front but highly speculative on commercial impact, as there are no disclosed clinical results, regulatory filings, or partnerships with device makers. Investors should see this as a long-term positioning move rather than a near-term revenue catalyst. The most important takeaway is that while Arecor has secured robust patent protection, realization of commercial value will require substantial further progress in clinical development, regulatory approval, and industry adoption.

Announcement summary

(AIM:AREC) Arecor Therapeutics plc announced the expansion of its international intellectual property protection for its proprietary AT278 product, an ultra-concentrated (500 U/mL) ultra-rapid acting insulin. The European Patent Office has granted a key patent protecting AT278 for use in automated insulin delivery (AID) systems, extending the patent term to at least 2039. The U.S. Patent and Trademark Office has also granted a separate patent for AT278 in AID systems, similarly extending protection to at least 2039 and adding to Arecor's portfolio of granted U.S. patents. The Indian Patent Office has granted a patent offering broad protection for the novel composition of AT278 in India. Arecor's concentrated ultra-rapid acting insulins are now protected by over 30 granted patents in major markets, covering concentrations from 100U/mL to over 500U/mL. Dr Jan Jezek, Chief Scientific Officer, stated that these new patents further strengthen the company's robust IP portfolio and expand coverage in key geographies, specifically for use in AID systems. In the United States, approximately four million people with diabetes require intensive insulin therapy and are candidates for AID systems. The U.S. AID market is underpenetrated, with only ~40% of Type 1 and ~5% of Type 2 diabetes patients using an AID system. Arecor has identified three significant opportunities for its insulins: (i) about one million people with diabetes in the U.S. require more than 100 units of insulin per day and currently have no three-day wear options available in AID systems; (ii) another one million AID system users seek longer wear time (seven days or more) and miniaturized pumps, but current cartridge capacities and insulin concentrations limit this; (iii) Arecor's insulins may be the first to enable a full closed loop (FCL), automated AID system, reducing user burden. The highest unmet need segment for longer wear and miniaturized pumps represents an approximately $3 billion insulin revenue opportunity in the U.S. alone, with the total U.S. insulin revenue market estimated at approximately $5 billion. Arecor's research and development is focused on its two proprietary insulin candidates, AT278 (500U/mL) and AT290 (200U/mL), designed to enable next generation AID systems. The company is also developing a novel oral delivery platform for peptides, with its first validation target being a GLP-1 receptor agonist. Arecor Therapeutics plc is quoted on AIM (AIM: AREC) and is based in Cambridge, UK.

Disagree with this article?